Plain-English translation of NCT06861088 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a supplement derived from a natural plant compound, can help prevent blood clots in people with advanced pancreatic cancer. People with pancreatic cancer have a high risk of developing blood clots, especially in the first few months after starting chemotherapy. This study will compare the medication at two different doses against a placebo to see which works best and whether it actually prevents these dangerous clots.
About one-third of pancreatic cancer patients develop blood clots, and the risk is highest during the first months of chemotherapy. There is currently no proven way to prevent these clots in this group of patients, so doctors are testing whether this treatment could help reduce this serious complication.
You likely qualify if…
You likely don't qualify if…
You would take capsules of either the medication or a placebo by mouth twice daily for 16 weeks while you receive your chemotherapy. The study is double-blind, meaning neither you nor your doctors will know whether you're receiving the active treatment or placebo. The researchers will track whether you develop any blood clots and monitor your blood work and overall health throughout the study period.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States